nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC2—prostate gland—prostate cancer	0.029	0.0818	CbGeAlD
Dihydroxyaluminium—VDAC3—prostate gland—prostate cancer	0.0242	0.0682	CbGeAlD
Dihydroxyaluminium—VDAC1—prostate gland—prostate cancer	0.023	0.0648	CbGeAlD
Dihydroxyaluminium—VDAC2—epithelium—prostate cancer	0.0213	0.0601	CbGeAlD
Dihydroxyaluminium—VDAC3—seminal vesicle—prostate cancer	0.0204	0.0576	CbGeAlD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TMOD1—prostate cancer	0.0199	0.118	CbGpPWpGaD
Dihydroxyaluminium—VDAC2—renal system—prostate cancer	0.0198	0.0558	CbGeAlD
Dihydroxyaluminium—TNNC1—prostate gland—prostate cancer	0.0197	0.0556	CbGeAlD
Dihydroxyaluminium—VDAC1—seminal vesicle—prostate cancer	0.0194	0.0548	CbGeAlD
Dihydroxyaluminium—VDAC1—epithelium—prostate cancer	0.0169	0.0476	CbGeAlD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—TMOD1—prostate cancer	0.0169	0.101	CbGpPWpGaD
Dihydroxyaluminium—VDAC3—renal system—prostate cancer	0.0165	0.0465	CbGeAlD
Dihydroxyaluminium—VDAC3—urethra—prostate cancer	0.0162	0.0456	CbGeAlD
Dihydroxyaluminium—VDAC1—renal system—prostate cancer	0.0157	0.0442	CbGeAlD
Dihydroxyaluminium—VDAC1—urethra—prostate cancer	0.0154	0.0434	CbGeAlD
Dihydroxyaluminium—TNNC1—Muscle contraction—TMOD1—prostate cancer	0.0133	0.0794	CbGpPWpGaD
Dihydroxyaluminium—VDAC2—testis—prostate cancer	0.0128	0.036	CbGeAlD
Dihydroxyaluminium—VDAC3—bone marrow—prostate cancer	0.0125	0.0351	CbGeAlD
Dihydroxyaluminium—VDAC1—bone marrow—prostate cancer	0.0118	0.0334	CbGeAlD
Dihydroxyaluminium—VDAC3—testis—prostate cancer	0.0106	0.03	CbGeAlD
Dihydroxyaluminium—VDAC1—testis—prostate cancer	0.0101	0.0286	CbGeAlD
Dihydroxyaluminium—TNNC1—MFAP5-mediated ovarian cancer cell motility and invasiveness—PRKCQ—prostate cancer	0.00935	0.0556	CbGpPWpGaD
Dihydroxyaluminium—VDAC2—lymph node—prostate cancer	0.00927	0.0261	CbGeAlD
Dihydroxyaluminium—TNNC1—testis—prostate cancer	0.00868	0.0245	CbGeAlD
Dihydroxyaluminium—VDAC1—Levonorgestrel—Ethinyl Estradiol—prostate cancer	0.00837	1	CbGdCrCtD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—VIM—prostate cancer	0.00814	0.0484	CbGpPWpGaD
Dihydroxyaluminium—VDAC3—lymph node—prostate cancer	0.00772	0.0218	CbGeAlD
Dihydroxyaluminium—TNNC1—MFAP5-mediated ovarian cancer cell motility and invasiveness—ITGB3—prostate cancer	0.00736	0.0438	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—lymph node—prostate cancer	0.00734	0.0207	CbGeAlD
Dihydroxyaluminium—TNNC1—Striated Muscle Contraction—VIM—prostate cancer	0.00691	0.0411	CbGpPWpGaD
Dihydroxyaluminium—TNNC1—lymph node—prostate cancer	0.00629	0.0177	CbGeAlD
Dihydroxyaluminium—TNNC1—Muscle contraction—VIM—prostate cancer	0.00546	0.0325	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—IGFBP6—prostate cancer	0.00421	0.025	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—TUSC3—prostate cancer	0.00421	0.025	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—GALNT3—prostate cancer	0.00375	0.0223	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—SSR2—prostate cancer	0.00375	0.0223	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—HERPUD1—prostate cancer	0.00343	0.0204	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—SPON2—prostate cancer	0.00343	0.0204	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—KLK3—prostate cancer	0.00319	0.019	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—KLK2—prostate cancer	0.003	0.0178	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—RPN2—prostate cancer	0.003	0.0178	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—MBTPS1—prostate cancer	0.003	0.0178	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—TCP1—prostate cancer	0.00284	0.0169	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—DNAJC3—prostate cancer	0.00271	0.0161	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—GCNT1—prostate cancer	0.0026	0.0155	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—PDIA3—prostate cancer	0.0025	0.0149	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—TPP1—prostate cancer	0.00242	0.0144	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—B4GALT4—prostate cancer	0.00242	0.0144	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—EIF3H—prostate cancer	0.00242	0.0144	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—F9—prostate cancer	0.00234	0.0139	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—MUC4—prostate cancer	0.00221	0.0132	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—RPL12—prostate cancer	0.00193	0.0115	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—HSP90B1—prostate cancer	0.00183	0.0109	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—EIF3A—prostate cancer	0.00177	0.0106	CbGpPWpGaD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—MME—prostate cancer	0.00157	0.00937	CbGpPWpGaD
Dihydroxyaluminium—Urticaria—Degarelix—prostate cancer	0.00156	0.00333	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Goserelin—prostate cancer	0.00156	0.00332	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Degarelix—prostate cancer	0.00155	0.00331	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Conjugated Estrogens—prostate cancer	0.00154	0.00329	CcSEcCtD
Dihydroxyaluminium—Dehydration—Mitoxantrone—prostate cancer	0.00154	0.00329	CcSEcCtD
Dihydroxyaluminium—Vomiting—Abiraterone—prostate cancer	0.00153	0.00326	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.00152	0.00325	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—GRP—prostate cancer	0.00151	0.00897	CbGpPWpGaD
Dihydroxyaluminium—Lung disorder—Epirubicin—prostate cancer	0.00151	0.00321	CcSEcCtD
Dihydroxyaluminium—Vomiting—Estrone—prostate cancer	0.00151	0.00321	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Nilutamide—prostate cancer	0.0015	0.00321	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Flutamide—prostate cancer	0.0015	0.00319	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Conjugated Estrogens—prostate cancer	0.00148	0.00316	CcSEcCtD
Dihydroxyaluminium—Nausea—Estramustine—prostate cancer	0.00147	0.00314	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—RPL10—prostate cancer	0.00146	0.00871	CbGpPWpGaD
Dihydroxyaluminium—Body temperature increased—Cabazitaxel—prostate cancer	0.00146	0.00312	CcSEcCtD
Dihydroxyaluminium—Dizziness—Nilutamide—prostate cancer	0.00145	0.0031	CcSEcCtD
Dihydroxyaluminium—Dizziness—Flutamide—prostate cancer	0.00145	0.00309	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Degarelix—prostate cancer	0.00145	0.00309	CcSEcCtD
Dihydroxyaluminium—Lightheadedness—Docetaxel—prostate cancer	0.00141	0.00302	CcSEcCtD
Dihydroxyaluminium—Nausea—Estrone—prostate cancer	0.00141	0.003	CcSEcCtD
Dihydroxyaluminium—Vomiting—Nilutamide—prostate cancer	0.0014	0.00298	CcSEcCtD
Dihydroxyaluminium—Chills—Goserelin—prostate cancer	0.00139	0.00297	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—prostate cancer	0.00139	0.00297	CcSEcCtD
Dihydroxyaluminium—Vomiting—Flutamide—prostate cancer	0.00139	0.00297	CcSEcCtD
Dihydroxyaluminium—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00137	0.00291	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Cabazitaxel—prostate cancer	0.00136	0.00291	CcSEcCtD
Dihydroxyaluminium—Pain—Bicalutamide—prostate cancer	0.00136	0.0029	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Degarelix—prostate cancer	0.00134	0.00287	CcSEcCtD
Dihydroxyaluminium—Oedema—Ethinyl Estradiol—prostate cancer	0.00134	0.00286	CcSEcCtD
Dihydroxyaluminium—Infection—Ethinyl Estradiol—prostate cancer	0.00133	0.00284	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Docetaxel—prostate cancer	0.00133	0.00284	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Docetaxel—prostate cancer	0.00133	0.00283	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ATF3—prostate cancer	0.00131	0.00782	CbGpPWpGaD
Dihydroxyaluminium—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00131	0.0028	CcSEcCtD
Dihydroxyaluminium—Back pain—Goserelin—prostate cancer	0.00131	0.00279	CcSEcCtD
Dihydroxyaluminium—Nausea—Nilutamide—prostate cancer	0.00131	0.00279	CcSEcCtD
Dihydroxyaluminium—Nausea—Flutamide—prostate cancer	0.0013	0.00277	CcSEcCtD
Dihydroxyaluminium—Dizziness—Degarelix—prostate cancer	0.0013	0.00277	CcSEcCtD
Dihydroxyaluminium—Back pain—Conjugated Estrogens—prostate cancer	0.0013	0.00277	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Capecitabine—prostate cancer	0.00129	0.00275	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Capecitabine—prostate cancer	0.00128	0.00274	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Goserelin—prostate cancer	0.00128	0.00272	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Cabazitaxel—prostate cancer	0.00127	0.0027	CcSEcCtD
Dihydroxyaluminium—Polyuria—Capecitabine—prostate cancer	0.00127	0.0027	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Conjugated Estrogens—prostate cancer	0.00126	0.00269	CcSEcCtD
Dihydroxyaluminium—Urticaria—Bicalutamide—prostate cancer	0.00126	0.00269	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Bicalutamide—prostate cancer	0.00126	0.00268	CcSEcCtD
Dihydroxyaluminium—Vomiting—Degarelix—prostate cancer	0.00125	0.00266	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—IGFBP3—prostate cancer	0.00124	0.00736	CbGpPWpGaD
Dihydroxyaluminium—Rhinitis—Estradiol—prostate cancer	0.00124	0.00263	CcSEcCtD
Dihydroxyaluminium—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00123	0.00262	CcSEcCtD
Dihydroxyaluminium—Dizziness—Cabazitaxel—prostate cancer	0.00122	0.00261	CcSEcCtD
Dihydroxyaluminium—Extravasation—Epirubicin—prostate cancer	0.00122	0.00261	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Epirubicin—prostate cancer	0.00121	0.00259	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Docetaxel—prostate cancer	0.00121	0.00258	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ACHE—prostate cancer	0.00121	0.00718	CbGpPWpGaD
Dihydroxyaluminium—Vertigo—Conjugated Estrogens—prostate cancer	0.0012	0.00257	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Estradiol—prostate cancer	0.00119	0.00253	CcSEcCtD
Dihydroxyaluminium—Vomiting—Cabazitaxel—prostate cancer	0.00118	0.00251	CcSEcCtD
Dihydroxyaluminium—Convulsion—Goserelin—prostate cancer	0.00117	0.0025	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Bicalutamide—prostate cancer	0.00117	0.00249	CcSEcCtD
Dihydroxyaluminium—Thirst—Capecitabine—prostate cancer	0.00117	0.00249	CcSEcCtD
Dihydroxyaluminium—Nausea—Degarelix—prostate cancer	0.00117	0.00249	CcSEcCtD
Dihydroxyaluminium—Convulsion—Conjugated Estrogens—prostate cancer	0.00116	0.00248	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—RPS19—prostate cancer	0.00116	0.00691	CbGpPWpGaD
Dihydroxyaluminium—Hyponatraemia—Docetaxel—prostate cancer	0.00115	0.00246	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Mitoxantrone—prostate cancer	0.00115	0.00245	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Prednisone—prostate cancer	0.00114	0.00244	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CTSD—prostate cancer	0.00114	0.0068	CbGpPWpGaD
Dihydroxyaluminium—Extravasation—Doxorubicin—prostate cancer	0.00113	0.00241	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—THBS1—prostate cancer	0.00113	0.0067	CbGpPWpGaD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—prostate cancer	0.00112	0.00239	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Capecitabine—prostate cancer	0.00112	0.00238	CcSEcCtD
Dihydroxyaluminium—Chills—Estradiol—prostate cancer	0.00111	0.00236	CcSEcCtD
Dihydroxyaluminium—Oedema—Goserelin—prostate cancer	0.0011	0.00236	CcSEcCtD
Dihydroxyaluminium—Nausea—Cabazitaxel—prostate cancer	0.0011	0.00234	CcSEcCtD
Dihydroxyaluminium—Infection—Goserelin—prostate cancer	0.0011	0.00234	CcSEcCtD
Dihydroxyaluminium—Oedema—Conjugated Estrogens—prostate cancer	0.00109	0.00233	CcSEcCtD
Dihydroxyaluminium—Infection—Conjugated Estrogens—prostate cancer	0.00109	0.00232	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Bicalutamide—prostate cancer	0.00109	0.00232	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Goserelin—prostate cancer	0.00108	0.0023	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CALR—prostate cancer	0.00107	0.00637	CbGpPWpGaD
Dihydroxyaluminium—Tachycardia—Conjugated Estrogens—prostate cancer	0.00107	0.00228	CcSEcCtD
Dihydroxyaluminium—Dehydration—Docetaxel—prostate cancer	0.00107	0.00228	CcSEcCtD
Dihydroxyaluminium—Urticaria—Ethinyl Estradiol—prostate cancer	0.00107	0.00227	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Ethinyl Estradiol—prostate cancer	0.00106	0.00226	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Capecitabine—prostate cancer	0.00106	0.00225	CcSEcCtD
Dihydroxyaluminium—Dizziness—Bicalutamide—prostate cancer	0.00105	0.00224	CcSEcCtD
Dihydroxyaluminium—Back pain—Estradiol—prostate cancer	0.00104	0.00221	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Epirubicin—prostate cancer	0.00104	0.00221	CcSEcCtD
Dihydroxyaluminium—Dehydration—Capecitabine—prostate cancer	0.00103	0.0022	CcSEcCtD
Dihydroxyaluminium—Hypotension—Goserelin—prostate cancer	0.00103	0.0022	CcSEcCtD
Dihydroxyaluminium—Chills—Mitoxantrone—prostate cancer	0.00103	0.0022	CcSEcCtD
Dihydroxyaluminium—Hypotension—Conjugated Estrogens—prostate cancer	0.00102	0.00218	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—ACE—prostate cancer	0.00102	0.00606	CbGpPWpGaD
Dihydroxyaluminium—Vomiting—Bicalutamide—prostate cancer	0.00101	0.00215	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000989	0.00211	CcSEcCtD
Dihydroxyaluminium—Coma—Epirubicin—prostate cancer	0.000974	0.00208	CcSEcCtD
Dihydroxyaluminium—Back pain—Mitoxantrone—prostate cancer	0.000967	0.00206	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Docetaxel—prostate cancer	0.000966	0.00206	CcSEcCtD
Dihydroxyaluminium—Vertigo—Estradiol—prostate cancer	0.000964	0.00206	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—prostate cancer	0.000958	0.00204	CcSEcCtD
Dihydroxyaluminium—Pain—Goserelin—prostate cancer	0.000944	0.00201	CcSEcCtD
Dihydroxyaluminium—Nausea—Bicalutamide—prostate cancer	0.000943	0.00201	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Mitoxantrone—prostate cancer	0.000942	0.00201	CcSEcCtD
Dihydroxyaluminium—Pain—Conjugated Estrogens—prostate cancer	0.000936	0.002	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Capecitabine—prostate cancer	0.000935	0.00199	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000918	0.00196	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—PLAUR—prostate cancer	0.000915	0.00545	CbGpPWpGaD
Dihydroxyaluminium—Coma—Doxorubicin—prostate cancer	0.000901	0.00192	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Epirubicin—prostate cancer	0.000898	0.00192	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Epirubicin—prostate cancer	0.000894	0.00191	CcSEcCtD
Dihydroxyaluminium—Dizziness—Ethinyl Estradiol—prostate cancer	0.000887	0.00189	CcSEcCtD
Dihydroxyaluminium—Urticaria—Goserelin—prostate cancer	0.000877	0.00187	CcSEcCtD
Dihydroxyaluminium—Oedema—Estradiol—prostate cancer	0.000876	0.00187	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Goserelin—prostate cancer	0.000873	0.00186	CcSEcCtD
Dihydroxyaluminium—Infection—Estradiol—prostate cancer	0.00087	0.00185	CcSEcCtD
Dihydroxyaluminium—Urticaria—Conjugated Estrogens—prostate cancer	0.000869	0.00185	CcSEcCtD
Dihydroxyaluminium—Convulsion—Mitoxantrone—prostate cancer	0.000866	0.00185	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Conjugated Estrogens—prostate cancer	0.000865	0.00184	CcSEcCtD
Dihydroxyaluminium—Chills—Etoposide—prostate cancer	0.000857	0.00183	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Estradiol—prostate cancer	0.000855	0.00182	CcSEcCtD
Dihydroxyaluminium—Vomiting—Ethinyl Estradiol—prostate cancer	0.000853	0.00182	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—prostate cancer	0.000831	0.00177	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—prostate cancer	0.000827	0.00176	CcSEcCtD
Dihydroxyaluminium—Oedema—Mitoxantrone—prostate cancer	0.000816	0.00174	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Goserelin—prostate cancer	0.000814	0.00174	CcSEcCtD
Dihydroxyaluminium—Infection—Mitoxantrone—prostate cancer	0.00081	0.00173	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000806	0.00172	CcSEcCtD
Dihydroxyaluminium—Back pain—Etoposide—prostate cancer	0.000804	0.00172	CcSEcCtD
Dihydroxyaluminium—Nausea—Ethinyl Estradiol—prostate cancer	0.000797	0.0017	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Mitoxantrone—prostate cancer	0.000796	0.0017	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Docetaxel—prostate cancer	0.000796	0.0017	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Epirubicin—prostate cancer	0.000777	0.00166	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Capecitabine—prostate cancer	0.00077	0.00164	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Docetaxel—prostate cancer	0.000765	0.00163	CcSEcCtD
Dihydroxyaluminium—Hypotension—Mitoxantrone—prostate cancer	0.000762	0.00163	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Goserelin—prostate cancer	0.000756	0.00161	CcSEcCtD
Dihydroxyaluminium—Pain—Estradiol—prostate cancer	0.000749	0.0016	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000749	0.0016	CcSEcCtD
Dihydroxyaluminium—Vertigo—Etoposide—prostate cancer	0.000747	0.00159	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Capecitabine—prostate cancer	0.000741	0.00158	CcSEcCtD
Dihydroxyaluminium—Dizziness—Goserelin—prostate cancer	0.00073	0.00156	CcSEcCtD
Dihydroxyaluminium—Dizziness—Conjugated Estrogens—prostate cancer	0.000723	0.00154	CcSEcCtD
Dihydroxyaluminium—Convulsion—Etoposide—prostate cancer	0.00072	0.00154	CcSEcCtD
Dihydroxyaluminium—Dehydration—Epirubicin—prostate cancer	0.00072	0.00153	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—prostate cancer	0.000719	0.00153	CcSEcCtD
Dihydroxyaluminium—Chills—Docetaxel—prostate cancer	0.000712	0.00152	CcSEcCtD
Dihydroxyaluminium—Vomiting—Goserelin—prostate cancer	0.000702	0.0015	CcSEcCtD
Dihydroxyaluminium—Pain—Mitoxantrone—prostate cancer	0.000698	0.00149	CcSEcCtD
Dihydroxyaluminium—Vomiting—Conjugated Estrogens—prostate cancer	0.000696	0.00148	CcSEcCtD
Dihydroxyaluminium—Urticaria—Estradiol—prostate cancer	0.000696	0.00148	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Estradiol—prostate cancer	0.000692	0.00148	CcSEcCtD
Dihydroxyaluminium—Chills—Capecitabine—prostate cancer	0.00069	0.00147	CcSEcCtD
Dihydroxyaluminium—Infection—Etoposide—prostate cancer	0.000674	0.00144	CcSEcCtD
Dihydroxyaluminium—Back pain—Docetaxel—prostate cancer	0.000668	0.00143	CcSEcCtD
Dihydroxyaluminium—Dehydration—Doxorubicin—prostate cancer	0.000666	0.00142	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Etoposide—prostate cancer	0.000662	0.00141	CcSEcCtD
Dihydroxyaluminium—Nausea—Goserelin—prostate cancer	0.000656	0.0014	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Epirubicin—prostate cancer	0.000652	0.00139	CcSEcCtD
Dihydroxyaluminium—Nausea—Conjugated Estrogens—prostate cancer	0.00065	0.00139	CcSEcCtD
Dihydroxyaluminium—Urticaria—Mitoxantrone—prostate cancer	0.000648	0.00138	CcSEcCtD
Dihydroxyaluminium—Back pain—Capecitabine—prostate cancer	0.000647	0.00138	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Estradiol—prostate cancer	0.000645	0.00138	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Mitoxantrone—prostate cancer	0.000645	0.00138	CcSEcCtD
Dihydroxyaluminium—Hypotension—Etoposide—prostate cancer	0.000634	0.00135	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—LEP—prostate cancer	0.000633	0.00377	CbGpPWpGaD
Dihydroxyaluminium—Vision blurred—Capecitabine—prostate cancer	0.000631	0.00134	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—prostate cancer	0.000603	0.00129	CcSEcCtD
Dihydroxyaluminium—Vertigo—Capecitabine—prostate cancer	0.000601	0.00128	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Mitoxantrone—prostate cancer	0.000601	0.00128	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Estradiol—prostate cancer	0.000599	0.00128	CcSEcCtD
Dihydroxyaluminium—Convulsion—Docetaxel—prostate cancer	0.000599	0.00128	CcSEcCtD
Dihydroxyaluminium—Pain—Etoposide—prostate cancer	0.00058	0.00124	CcSEcCtD
Dihydroxyaluminium—Dizziness—Estradiol—prostate cancer	0.000579	0.00123	CcSEcCtD
Dihydroxyaluminium—Oedema—Docetaxel—prostate cancer	0.000564	0.0012	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Prednisone—prostate cancer	0.000562	0.0012	CcSEcCtD
Dihydroxyaluminium—Infection—Docetaxel—prostate cancer	0.00056	0.00119	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Mitoxantrone—prostate cancer	0.000558	0.00119	CcSEcCtD
Dihydroxyaluminium—Vomiting—Estradiol—prostate cancer	0.000557	0.00119	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Docetaxel—prostate cancer	0.00055	0.00117	CcSEcCtD
Dihydroxyaluminium—Oedema—Capecitabine—prostate cancer	0.000546	0.00116	CcSEcCtD
Dihydroxyaluminium—Infection—Capecitabine—prostate cancer	0.000542	0.00116	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—INS—prostate cancer	0.00054	0.00322	CbGpPWpGaD
Dihydroxyaluminium—Urticaria—Etoposide—prostate cancer	0.000539	0.00115	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Epirubicin—prostate cancer	0.000537	0.00114	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Etoposide—prostate cancer	0.000536	0.00114	CcSEcCtD
Dihydroxyaluminium—Vertigo—Prednisone—prostate cancer	0.000535	0.00114	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Capecitabine—prostate cancer	0.000533	0.00114	CcSEcCtD
Dihydroxyaluminium—Hypotension—Docetaxel—prostate cancer	0.000527	0.00112	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—IGF1—prostate cancer	0.000523	0.00311	CbGpPWpGaD
Dihydroxyaluminium—Nausea—Estradiol—prostate cancer	0.00052	0.00111	CcSEcCtD
Dihydroxyaluminium—Vomiting—Mitoxantrone—prostate cancer	0.000519	0.00111	CcSEcCtD
Dihydroxyaluminium—Convulsion—Prednisone—prostate cancer	0.000516	0.0011	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Epirubicin—prostate cancer	0.000516	0.0011	CcSEcCtD
Dihydroxyaluminium—Hypotension—Capecitabine—prostate cancer	0.00051	0.00109	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—MMP2—prostate cancer	0.000506	0.00301	CbGpPWpGaD
Dihydroxyaluminium—Hypersensitivity—Etoposide—prostate cancer	0.0005	0.00107	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—prostate cancer	0.000497	0.00106	CcSEcCtD
Dihydroxyaluminium—Oedema—Prednisone—prostate cancer	0.000486	0.00104	CcSEcCtD
Dihydroxyaluminium—Nausea—Mitoxantrone—prostate cancer	0.000485	0.00103	CcSEcCtD
Dihydroxyaluminium—Infection—Prednisone—prostate cancer	0.000483	0.00103	CcSEcCtD
Dihydroxyaluminium—Pain—Docetaxel—prostate cancer	0.000482	0.00103	CcSEcCtD
Dihydroxyaluminium—Chills—Epirubicin—prostate cancer	0.00048	0.00102	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—prostate cancer	0.000477	0.00102	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Prednisone—prostate cancer	0.000475	0.00101	CcSEcCtD
Dihydroxyaluminium—Pain—Capecitabine—prostate cancer	0.000467	0.000996	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Etoposide—prostate cancer	0.000464	0.00099	CcSEcCtD
Dihydroxyaluminium—Back pain—Epirubicin—prostate cancer	0.000451	0.000961	CcSEcCtD
Dihydroxyaluminium—Dizziness—Etoposide—prostate cancer	0.000449	0.000957	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Docetaxel—prostate cancer	0.000446	0.000951	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—prostate cancer	0.000445	0.000948	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Epirubicin—prostate cancer	0.000439	0.000937	CcSEcCtD
Dihydroxyaluminium—Urticaria—Capecitabine—prostate cancer	0.000434	0.000925	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Capecitabine—prostate cancer	0.000432	0.00092	CcSEcCtD
Dihydroxyaluminium—Vomiting—Etoposide—prostate cancer	0.000431	0.00092	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CXCL8—prostate cancer	0.00042	0.0025	CbGpPWpGaD
Dihydroxyaluminium—Vertigo—Epirubicin—prostate cancer	0.000419	0.000893	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—prostate cancer	0.000417	0.00089	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Docetaxel—prostate cancer	0.000416	0.000886	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—prostate cancer	0.000406	0.000867	CcSEcCtD
Dihydroxyaluminium—Convulsion—Epirubicin—prostate cancer	0.000404	0.000861	CcSEcCtD
Dihydroxyaluminium—Nausea—Etoposide—prostate cancer	0.000403	0.00086	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Capecitabine—prostate cancer	0.000402	0.000858	CcSEcCtD
Dihydroxyaluminium—VDAC1—Metabolism of proteins—CTNNB1—prostate cancer	0.000388	0.00231	CbGpPWpGaD
Dihydroxyaluminium—Vertigo—Doxorubicin—prostate cancer	0.000387	0.000826	CcSEcCtD
Dihydroxyaluminium—Urticaria—Prednisone—prostate cancer	0.000386	0.000824	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Docetaxel—prostate cancer	0.000386	0.000823	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Prednisone—prostate cancer	0.000384	0.00082	CcSEcCtD
Dihydroxyaluminium—Oedema—Epirubicin—prostate cancer	0.00038	0.000811	CcSEcCtD
Dihydroxyaluminium—Infection—Epirubicin—prostate cancer	0.000378	0.000806	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—prostate cancer	0.000374	0.000797	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Capecitabine—prostate cancer	0.000374	0.000797	CcSEcCtD
Dihydroxyaluminium—Dizziness—Docetaxel—prostate cancer	0.000373	0.000795	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Epirubicin—prostate cancer	0.000371	0.000792	CcSEcCtD
Dihydroxyaluminium—Dizziness—Capecitabine—prostate cancer	0.000361	0.00077	CcSEcCtD
Dihydroxyaluminium—Vomiting—Docetaxel—prostate cancer	0.000359	0.000765	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Prednisone—prostate cancer	0.000358	0.000764	CcSEcCtD
Dihydroxyaluminium—Hypotension—Epirubicin—prostate cancer	0.000355	0.000758	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—prostate cancer	0.000352	0.000751	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—prostate cancer	0.00035	0.000746	CcSEcCtD
Dihydroxyaluminium—Vomiting—Capecitabine—prostate cancer	0.000347	0.00074	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—prostate cancer	0.000344	0.000733	CcSEcCtD
Dihydroxyaluminium—Nausea—Docetaxel—prostate cancer	0.000335	0.000714	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Prednisone—prostate cancer	0.000333	0.00071	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—prostate cancer	0.000329	0.000701	CcSEcCtD
Dihydroxyaluminium—Pain—Epirubicin—prostate cancer	0.000325	0.000694	CcSEcCtD
Dihydroxyaluminium—Nausea—Capecitabine—prostate cancer	0.000324	0.000692	CcSEcCtD
Dihydroxyaluminium—Dizziness—Prednisone—prostate cancer	0.000322	0.000686	CcSEcCtD
Dihydroxyaluminium—Vomiting—Prednisone—prostate cancer	0.000309	0.000659	CcSEcCtD
Dihydroxyaluminium—Urticaria—Epirubicin—prostate cancer	0.000302	0.000644	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—prostate cancer	0.000301	0.000642	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Epirubicin—prostate cancer	0.000301	0.000641	CcSEcCtD
Dihydroxyaluminium—Nausea—Prednisone—prostate cancer	0.000289	0.000616	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Epirubicin—prostate cancer	0.00028	0.000598	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—prostate cancer	0.00028	0.000596	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—prostate cancer	0.000278	0.000593	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Epirubicin—prostate cancer	0.00026	0.000555	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—prostate cancer	0.000259	0.000553	CcSEcCtD
Dihydroxyaluminium—Dizziness—Epirubicin—prostate cancer	0.000252	0.000536	CcSEcCtD
Dihydroxyaluminium—Vomiting—Epirubicin—prostate cancer	0.000242	0.000516	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—prostate cancer	0.000241	0.000514	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—prostate cancer	0.000233	0.000496	CcSEcCtD
Dihydroxyaluminium—Nausea—Epirubicin—prostate cancer	0.000226	0.000482	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—prostate cancer	0.000224	0.000477	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—prostate cancer	0.000209	0.000446	CcSEcCtD
